Other Name(s): BCL-XL, Bcl-xL, BCLXL
Drug Target Analysis Report Drug Target Analysis Report Content

About the Target

Based on the provided context information, here is a comprehensive summary of key viewpoints related to BCL2L1 (BCL-XL):

BCL-XL is a protein that plays a role in regulating apoptosis in both normal cells and during flavivirus infection [1]. It delays apoptosis in normal cells, allowing the virus to spread to neighboring cells and contribute to high pathogenicity. However, inhibiting BCL-XL accelerates apoptosis upon infection and inhibits viral dissemination [1].

BCL-XL is an isoform of Bcl-x that inhibits the activation of Bax and Bak, thus preventing the loss of mitochondrial outer membrane integrity and release of cytochrome c [2]. Therefore, BCL-XL is considered anti-apoptotic.

Another isoform of Bcl-x, Bcl-xS, can inhibit BCL-XL and, when activated, leads to the loss of mitochondrial outer membrane integrity and subsequent apoptotic cell death [2].

The expression of BCL-XL is regulated by PARK2 ubiquitin E3 ligase, which controls its levels to regulate cell death [3].

In cancer cells, pro-survival proteins like BCL-2, BCL-XL, and MCL-1 bind to and inhibit pro-apoptotic proteins, such as BAX and BAK [4]. However, when cells are treated with certain combinations of compounds, the pro-apoptotic proteins are released and activated, leading to efficient induction of apoptosis [4].

BCL-XL, along with BCL-2, is involved in B-CLL resistance to apoptosis, contributing to cell survival and resistance to cell death [5]. The interaction between NTSR2 and TrkB receptors, strengthened by BDNF activation, triggers pro-survival pathways via phosphorylation of NTSR2 and the expression of downstream anti-apoptotic proteins, including BCL-XL [5]. However, inhibiting NTSR2 can re-establish B-CLL apoptosis [5].

These findings highlight the diverse roles of BCL2L1 (BCL-XL) in regulating apoptosis, its involvement in viral pathogenicity, and its relevance in cancer and B-CLL survival.

Figure [1]

Figure [2]

Figure [3]

Figure [4]

Figure [5]

Note: If you are interested in the full version of this target analysis report, or if you'd like to learn how our AI-powered BDE-Chem can design therapeutic molecules to interact with the BCL2L1 target at a cost 90% lower than traditional approaches, please feel free to contact us at BD@silexon.ai.

More Common Targets

ABCB1 | ABCG2 | ACE2 | AHR | AKT1 | ALK | AR | ATM | BAX | BCL2 | BCL2L1 | BECN1 | BRAF | BRCA1 | CAMP | CASP3 | CASP9 | CCL5 | CCND1 | CD274 | CD4 | CD8A | CDH1 | CDKN1A | CDKN2A | CREB1 | CXCL8 | CXCR4 | DNMT1 | EGF | EGFR | EP300 | ERBB2 | EREG | ESR1 | EZH2 | FN1 | FOXO3 | HDAC9 | HGF | HMGB1 | HSP90AA1 | HSPA4 | HSPA5 | IDO1 | IFNA1 | IGF1 | IGF1R | IL17A | IL6 | INS | JUN | KRAS | MAPK1 | MAPK14 | MAPK3 | MAPK8 | MAPT | MCL1 | MDM2 | MET | MMP9 | MTOR | MYC | NFE2L2 | NLRP3 | NOTCH1 | PARP1 | PCNA | PDCD1 | PLK1 | PRKAA1 | PRKAA2 | PTEN | PTGS2 | PTK2 | RELA | SIRT1 | SLTM | SMAD4 | SOD1 | SQSTM1 | SRC | STAT1 | STAT3 | STAT5A | TAK1 | TERT | TLR4 | TNF | TP53 | TXN | VEGFA | YAP1